SemaThera

Entreprise en démarrage développant des inhibiteurs de SEMA 3A - Startup company developing SEMA 3A inhibitors / Dr Mike Sapieha HMR, Montreal, Québec, Canada

[Sweet Biopharma Day @SweetPharmaDay]

@SweetPharmaDay is looking for innovative start-ups and small companies in #biotechnology!

Interested in becoming one of the “Sweet-16”? Submit your application to [email protected] by September 7.

👉 Learn more: https://t.co/KhvRPvvI4y

@BIO_Qc @AmorChem @CQDM_Canada

[SemaThera @Sema_Thera]

@tedcruz The blind leading the blind comes to mind with yet another ridiculous quote from a US politician that clearly has no idea of what is happening in the real world.

[SemaThera @Sema_Thera]

Mike Sapieha receives Cogan Award at ARVO 2019

[SemaThera @Sema_Thera]

Congrats to our COO, Mike Sapieha a newly elected fellow of the Royal Society of Canada. https://t.co/G4s9wOMvzV

[AmorChem @AmorChem]

Delighted to share this news of Inversago Pharma! https://t.co/fAUCh2porp

[Latest News from Business Wire @NewsFromBW]

Inversago Pharma Receives $7 Million in Series A Financing https://t.co/9PQ1iw8sSm

[Jo VB 🇨🇦 @jovbetsbr]

Synthetic #cannabinoid #CB1 receptor blockers poised for a comeback after #Montreal based @inversago pharma announces $7M Series A funding. #T1D #PWS #Lifesciences https://t.co/cPaYg2L5Su.

[Peter van der Velden @Petervencap]

The Lumira Ventures team is pleased to welcome to Veteran Life Sciences Executive Jason D. Hanson to enGene as the company's new Chief Executive Officer and President #lumiraventures https://t.co/4NBHfoKg2E

[Peter van der Velden @Petervencap]

Lumira Ventures portfolio company Antiva Biosciences completes $15 Million Series C-1 financing with Hillhouse Capital, Sirona Capital and existing investors including Canann, Sofinnova, Brace Pharma, Osage and Lumira - https://t.co/ezT0Aerd3p

[SemaThera @Sema_Thera]

Congrats Mike | CSO SemaThera https://t.co/HJEgk99Kf2

[Josée Legault @JoseeLegault]

Annulation de SLAV: un dangereux précédent | Mon billet JDM https://t.co/ISMF0I0OWt #SLAV

[Avitia @avitiabio]

"AI-enabled tools will quickly feel invisible, making way for a more personal doctor-to-patient experience. #AI can empower clinicians to do their best work by freeing up their attention to do what only a human can."

Look into the future courtesy... https://t.co/LA9HokDOT5

[AUTM @AUTM]

Technology Licensing Officer - Software and IT - Massachusetts Institute of Technology - Cambridge, MA https://t.co/APQuUI8r8X

[IRICoR @IRICoR_]

Second session: Study case of SpecificiT Pharma Inc. @PierreBeauparlant CEO of SpecificiT, Grazia Maion from @univalor, Alain Dumont from GGD, Ines Holzbaur @AmorChem

[SemaThera @Sema_Thera]

@iBiosolutions Felicitations!

[Immune Biosolutions @iBiosolutions]

Thanks to Minister Barrette’s support https://t.co/5ynFahZwtV

[Lydiane Gaborieau @LydianeG]

Veronique Bougie from @corbin_thera doing a great job pitching at the @BIOTECanada dragon’s den!!

[Maxime Ranger @max_ranger]

AMORCHEM ANNOUNCES AN INVESTMENT BY FONDACTION IN ITS FUND
https://t.co/bBSZTv7i9U

[Retina Global @RetinaGlobal1]

SEMA 3A was identified as a novel target for ocular diseasesthat promotes vascular leakage and contributes to diabetes-related macular edema. https://t.co/qHU7j3PfCi #Diabetes #DME @Sema_Thera

[SemaThera @Sema_Thera]

SemaThera signed an agreement with Chiome for the exclusivity on the anti-SEMA 3A monoclonal antibody https://t.co/ECdatb1UCL